 This is a randomized, placebo controlled, four way crossover thorough QT study to evaluate the effect of repeat dose GSK2190915 on the QTc interval in healthy male and female subjects. Approximately 48 subjects will receive oral placebo, GSK2190915 100mg or 1000mg and moxifloxacin 400mg. GSK2190915 or matching placebo will be given once daily for 5 days with a moxifloxacin matching placebo given on Day 5. Moxifloxacin positive control will be given as a single-blind single dose on Day 5 with placebo administered on Days 1-4. Individual time-matched changes from baseline in QTcF difference from placebo for GSK2190915 will be determined 0-24 hours after dosing on Day 5 primary endpoint. Secondary endpoints will include changes from baseline in QTcF, QTcB and QT interval at each timepoint after 5 days dosing of GSK2190915 and single dose moxifloxacin 400mg. Plasma concentrations on Day 5 0-24 hours and pharmacokinetic parameters of GSK2190915 will also be derived. 